ObsEva SA. (NASDAQ: OBSV) shares climbed 9.49%, or $0.129 per share, as on 12:04:55 est today. Opening the day at $1.39, 78,035 shares of ObsEva SA. have exchanged hands and the stock has traded between $1.49 and $1.38.  

Already the company has moved YTD 31.66%.

ObsEva SA. expects its next earnings on 2022-05-17.

For technical charts, analysis, and more on ObsEva SA. visit the company profile.

About ObsEva SA.

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor.

To get more information on ObsEva SA. and to follow the company's latest updates, you can visit the company's profile page here: ObsEva SA.'s Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

Big Lots Down 18% in Premarket Trading Friday on Surprise Missed Earnings

Modine Posts Strong Rebound in Fiscal Q4, Raises 2023 Guidance

Dollar Tree Posts Record First Quarter, Leads Nasdaq Gainers

Kohl's Still in Play To Be Acquired

Chinook Therapeutics Raises $105 Million for Kidney Disease Therapies

Market Conditions Driving Higher Base Level for VIX Volatility Index

Will New AT&T, Dish Co-opetition Deal Work: Jeff Kagan

Cisco Down 12% in Premarket Trading Thursday After Top Line Miss and Lower Forecast